靶向VIM的FA变化与TcMRgFUS丘脑毁损术后临床结局的相关性
本回顾性先导研究分析12例药物难治性特发性震颤患者接受TcMRgFUS丘脑毁损术前后靶向VIM的rFA变化及其与临床结局的关系。治疗后rFA显著下降,复发组rFA持续高于改善组,术后1天rFA与1年CRST评分显著正相关,最佳预测切点为0.54。作者认为FA或可作为早期预测临床结局的影像生物标志物。
要点
- 12例难治性特发性震颤患者接受TcMRgFUS丘脑毁损术,1年随访时8例震颤缓解、4例复发。
- 靶向VIM的rFA在术前、术后1天、术后1年分别为1.12±0.15、0.44±0.13、0.82±0.22(p<0.001)。
- 术后1天rFA预测1年症状改善的最佳切点为0.54。
核心结论
- TcMRgFUS丘脑毁损术使靶向VIM的rFA在术后1天和1年均显著下降。
- 术后1天rFA与1年CRST评分显著正相关(p<0.01),最佳预测切点为0.54。
- 作者认为FA或可作为TcMRgFUS丘脑毁损术治疗特发性震颤后早期预测临床结局的影像生物标志物。
研究设计与样本
- 回顾性分析12例药物难治性特发性震颤患者(平均年龄76.5岁)接受TcMRgFUS丘脑毁损术并靶向VIM的临床与影像数据。
- 治疗前及治疗后1年计算CRST评分;术前、术后1天及术后1年测量rFA(靶向VIM的FA值与对侧VIM的FA值之比)。
主要发现
- TcMRgFUS丘脑毁损术耐受良好,未记录长期并发症。
- 1年随访时8例震颤缓解(改善组),4例持续震颤(复发组)。
- 全队列术前、术后1天、术后1年平均rFA分别为1.12±0.15、0.44±0.13、0.82±0.22(p<0.001)。
- 复发组rFA持续高于改善组,术后1天(p<0.05)和术后1年(p<0.01)差异达统计学显著。
- 术后1天靶向VIM的rFA与术后1年CRST评分呈显著正相关(p<0.01);ROC曲线分析显示术后1天rFA预测1年症状改善的最佳切点为0.54。
关键数值与推荐
- rFA定义为靶向VIM的FA值与对侧VIM的FA值之比。
- 全队列术前rFA为1.12±0.15,术后1天为0.44±0.13,术后1年为0.82±0.22(p<0.001)。
- 复发组rFA持续高于改善组,术后1天p<0.05,术后1年p<0.01。
- 术后1天rFA预测1年症状改善的最佳切点为0.54。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study evaluated changes of fractional anisotropy (FA) in the ventral intermediate nucleus (VIM) of the thalamus after transcranial MR-guided focused ultrasound (TcMRgFUS) thalamotomy and their associations with clinical outcome. METHODS: Clinical and radiological data of 12 patients with medically refractory essential tremor (mean age 76.5 years) who underwent TcMRgFUS thalamotomy with VIM targeting were analyzed retrospectively. The Clinical Rating Scale for Tremor (CRST) score was calculated before and at 1 year after treatment. Measurements of the relative FA (rFA) values, defined as ratio of the FA value in the targeted VIM to the FA value in the contralateral VIM, were performed before thalamotomy, and 1 day and 1 year thereafter. RESULTS: TcMRgFUS thalamotomy was well tolerated and no long-term complications were noted. At 1-year follow-up, 8 patients demonstrated relief of tremor (improvement group), whereas in 4 others persistent tremor was noted (recurrence group). In the entire cohort, mean rFA values in the targeted VIM before treatment, and at 1 day and 1 year after treatment, were 1.12 ± 0.15, 0.44 ± 0.13, and 0.82 ± 0.22, respectively (p < 0.001). rFA values were consistently higher in the recurrence group compared with the improvement group, and the difference reached statistical significance at 1 day (p < 0.05) and 1 year (p < 0.01) after treatment. There was a statistically significant (p < 0.01) positive correlation between rFA values in the targeted VIM at 1 day after thalamotomy and CRST score at 1 year after treatment. Receiver operating characteristic curve analysis revealed that the optimal cutoff value of rFA at 1 day after thalamotomy for prediction of symptomatic improvement at 1-year follow-up is 0.54. CONCLUSIONS: TcMRgFUS thalamotomy results in significant decrease of rFA in the targeted VIM, at both 1 day and 1 year after treatment. Relative FA values at 1 day after treatment showed significant correlation with CRST score at 1-year follow-up. Therefore, FA may be considered a possible imaging biomarker for early prediction of clinical outcome after TcMRgFUS thalamotomy for essential tremor.
引用
- Hori H, Yamaguchi T, Konishi Y, et al. Correlation between fractional anisotropy changes in the targeted ventral intermediate nucleus and clinical outcome after transcranial MR-guided focused ultrasound thalamotomy for essential tremor: results of a pilot study. J Neurosurg. 2019. PMID: 30771772. doi:10.3171/2018.10.JNS18993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。